Genital herpes is common in the United States.
The most recent Centers for Disease Control and Prevention estimates show there were 572,000 new genital herpes infections in the United States during the year 2018. Comparatively 1-in-6 American women between the ages of 14 years old and 49 years old are said to carry the HSV-2 virus, which causes genital sores, and 1-in-12 men in the same age group, according to Herstat, makers of a new OTC genital sore treatment.
The Jackson, Wyo.-based company said that despite it being a common condition, genital herpes sufferers are often subjected to the negative and unwarranted social stigma of the ailment, which is precisely why the packaging for GST has been thoughtfully designed with the consumer’s natural desire to shop in-store with privacy in mind.
“We know from our extensive global experience within the herpes space that genital herpes sufferers will regularly reach for topical cold sore products, which they will use alongside taking oral prescription meds,” the company said. “With this in mind, we suggest that Herstat GST sits as comfortably within the personal care/feminine care section as it does adjacent to existing Herstat products in the cold sore assortment.”
For sufferers of cold sores (HSV-1) and genital sores (HSV-2), the Herstat brand is increasingly becoming synonymous with products that provide both fast acting relief and highly efficacious treatment for their unwanted symptoms, the company said.
The product will be available to retail pharmacies and mass retail Oct. 1.